Founded in Copenhagen in 1923, ALK-Abelló A/S has developed into a global, research-driven pharmaceutical company specializing in allergy and allergy immunotherapy. Headquartered in Hørsholm, Denmark, the company has built a leading international position in the long-term treatment of allergy, supported by deep scientific expertise in allergens, immunological mechanisms, and the relationship between allergy and respiratory diseases, including allergic asthma. ALK operates in 46 markets, has offices in more than 20 countries, manufacturing facilities in Denmark, France, Spain, and the United States, and reaches approximately 2.6 million patients annually worldwide. The company employs around 2,800 people globally and delivered 15% revenue growth in 2025, underscoring the strength of its highly specialized, internationally scalable business model.
Updated 2026-03-19